The ImClone Alumni: Where Are They Now?

4/7/11Follow @xconomy

[Updated: 10:20 pm, 4/15/11] ImClone Systems is the biotech company that Martha Stewart made famous, but after the scandalous headlines faded away, it has left a lasting imprint on New York.

The ImClone story has been told many times over, about the 2001 insider trading allegation that ended up landing both ImClone CEO Sam Waksal and his famous friend in jail. Both of them are now back doing their thing—Martha at her eponymous home lifestyle company, and Waksal as the CEO of a New York-based biotech startup called Kadmon Pharmaceuticals.

Despite the initial FDA rejection that led to the insider trading scandal, and a string of embarrassing revelations about the company, ImClone actually bounced back to live up to its promise. The company, founded in 1984, won FDA clearance to start selling its targeted antibody drug for colorectal cancer, cetuximab (Erbitux) in 2004. The drug caught on with cancer physicians around the world, generating $1.3 billion in worldwide sales in 2007. ImClone, after initially rebuffing a takeover offer from its partner Bristol-Myers Squibb, agreed to be acquired for a richer bid of $70 a share, or $6.5 billion, by Eli Lilly (NYSE: LLY) in October 2008.

Lilly agreed to keep the ImClone name alive, and about two years after the acquisition, Lilly said it is moving 140 ImClone scientists into a high-profile biotech development along New York’s East River. But ImClone said it had 1,128 employees in its last annual report, with almost 1,000 of them at its New Jersey facilities, and the rest in its New York headquarters. Where are they now?

To get a sense of the kind of legacy the company still has today, I’ve put together a directory with links to help alumni connect and re-connect. Many have stayed at ImClone, but quite a few have moved on. This alphabetical list includes not just the Waksals, but also the anonymous folks who did much of the work to make ImClone into what it was. The list includes 143 names at last count.

Now here’s the part where you can help. If you or someone you know would like to be included, please send me a note. If you see any information below that’s out of date or incorrect, let me know and I’ll fix it. You can reach me at ltimmerman@xconomy.com.

Over time, I hope this story can become a richer and more valuable resource for ImClone alumni. Here’s the list in alphabetical order, with the most updated titles and affiliations I found online.

Michael Bailey, chief commercial officer, Aveo Pharmaceuticals

Tony Barberio, assistant vice president of facilities, ImClone Systems, a subsidiary of Eli Lilly

Michael Barry, vice president of process development-downstream, ImClone Systems, a subsidiary of Eli Lilly

Brian Batchelder, chief financial officer, ImClone Systems, a subsidiary of Eli Lilly

Carole Beer, vice president of global quality, ImClone Systems, a subsidiary of Eli Lilly

Meghna Bhatt, human resources specialist I, ImClone Systems, a subsidiary of Eli Lilly

Peter Bohlen, biotechnology consultant

Christine Bonacci, senior director, metrology, ImClone Systems, a subsidiary of Eli Lilly

Peter Borzilleri, financial consultant, New York City Apparel Company … Next Page »

Single Page Currently on Page: 1 2 3 4 5 6

By posting a comment, you agree to our terms and conditions.

  • G. Chu

    It is the propagandist media that made ImClone “famous” and created the “scandalous headlines.” Not Martha Stewart, who did nothing wrong in her perfectly legal stock sale. She had nothing to do with Waksal’s criminal insider trading; and she was involved in no “insider trading scandal,” a media-created fiction.

    Martha Stewart “ended up landing…in jail” because of grossly incompetent legal representation, that enabled and facilitated the abuse and misuse of the criminal justice system on her for political gain.

    Almost 8,000,000 ImClone shares were traded; Martha Stewart made a legal sale of 3,928 shares. Timmerman’s embedded linking of Martha Stewart to the insider trading of ImClone and Waksal is propagandist with no journalistic integrity.

    Timmerman states ImClone initially rebuffed “a takeover offer from its partner Bristol-Myers Squibb.” But where is the fact from Timmerman that Martha Stewart made the decision to sell ALL of her ImClone stock in the tender offer from Bristol-Myers Squibb? How does her decision to sell ALL of her ImClone stock to Bristol-Myers Squibb jive with “rebuff” and “insider trading”? Clearly, Martha Stewart made her independent decision to sell ALL of her ImClone stock based on sound investment management principles.

    The political and criminal persecution of Martha Stewart is a blot on American democracy; and she is owed a presidential pardon from President Barack Obama.